

David A Reardon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/801158/publications.pdf>

Version: 2024-02-01

242
papers

34,102
citations

6613

79
h-index

3915

177
g-index

247
all docs

247
docs citations

247
times ranked

29216
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
2	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	1.2	38
3	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
4	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
5	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
6	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
7	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, xv-xvi.	2.2	0
8	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	2.2	5
9	Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. <i>Neuro-Oncology</i> , 2022, 24, 951-963.	1.2	44
10	Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. <i>Neuro-Oncology Practice</i> , 2022, 9, 201-207.	1.6	3
11	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vda025.	0.7	18
12	Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 367-380.	2.0	0
13	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	7.0	20
14	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	1.2	13
15	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
16	Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. <i>American Journal of Neuroradiology</i> , 2022, 43, 675-681.	2.4	12
17	DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2077-TPS2077.	1.6	2
18	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	7.0	100

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	7.0	129
20	Adolescent and young adult neuro-oncology: a comprehensive review. <i>Neuro-Oncology Practice</i> , 2021, 8, 236-246.	1.6	5
21	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	1.2	28
22	Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 515-522.	2.9	18
23	IDH-mutant gliomas with additional class-defining molecular events. <i>Modern Pathology</i> , 2021, 34, 1236-1244.	5.5	13
24	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	28.9	210
25	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	1.2	66
26	The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 235-248.	1.7	8
27	Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. <i>Acta Neurochirurgica</i> , 2021, 163, 1883-1894.	1.7	11
28	Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma. <i>Med</i> , 2021, 2, 450-452.	4.4	4
29	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 679331.	2.8	4
30	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
31	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
32	Glial and myeloid heterogeneity in the brain tumour microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 786-802.	28.4	83
33	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vda125.	0.7	30
34	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	4.1	56
35	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
36	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	10.7	129

#	ARTICLE	IF	CITATIONS
37	Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. <i>Neuro-Oncology</i> , 2020, 22, 369-380.	1.2	13
38	An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning. <i>Neurosurgery</i> , 2020, 86, E184-E192.	1.1	75
39	Socioeconomic Disparities Associated With <i>MGMT</i> Promoter Methylation Testing for Patients With Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1972.	7.1	22
40	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
41	A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. <i>Investigational New Drugs</i> , 2020, 38, 1784-1795.	2.6	38
42	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	1.2	19
43	Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. <i>Scientific Reports</i> , 2020, 10, 8766.	3.3	24
44	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	9.7	43
45	NRG/TOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	4.1	25
46	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. <i>Scientific Reports</i> , 2020, 10, 5095.	3.3	28
47	Deep Learning Detection of Cancer Metastases to the Brain on MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1227-1236.	3.4	71
48	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020, 22, 1568-1579.	1.2	38
49	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	1.2	37
50	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
51	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
52	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
53	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii11-ii11.	1.2	1
54	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	1.2	3

#	ARTICLE	IF	CITATIONS
55	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii106-ii106.	1.2	1
56	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	1.2	1
57	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	1.2	5
58	CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2020, 22, ii35-ii35.	1.2	0
59	BIOM-61. FUNCTIONAL DIAGNOSTIC TESTING OF LIVE-CELL DRUG RESPONSE USING 3D PATIENT DERIVED GLIOBLASTOMA SPHEROIDS ON THE INCUCYTE PLATFORM. <i>Neuro-Oncology</i> , 2020, 22, ii15-ii15.	1.2	0
60	CTIM-07. IDENTIFICATION OF A BASELINE BIOMARKER ASSOCIATED WITH TUMOR RESPONSES IN A PHASE I/IIa TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2020, 22, ii34-ii34.	1.2	0
61	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii138-ii139.	1.2	0
62	EPID-35. CLINICAL TRIAL ENROLLMENT RATE AMONG ADOLESCENT AND YOUNG ADULTS WITH CENTRAL NERVOUS SYSTEM TUMOR AT DANA-FARBER CANCER INSTITUTE (DFCI). <i>Neuro-Oncology</i> , 2020, 22, ii86-ii86.	1.2	0
63	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii164-ii164.	1.2	0
64	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2020, 22, ii186-ii187.	1.2	0
65	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii80-ii81.	1.2	1
66	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii40.	1.2	0
67	BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii8-ii9.	1.2	0
68	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	1.2	114
69	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
70	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	7.0	166
71	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	7.7	386
72	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84

#	ARTICLE	IF	CITATIONS
73	Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. <i>Theranostics</i> , 2019, 9, 6284-6299.	10.0	78
74	Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 327-336.	2.3	38
75	Survival and prognostic factors in surgically treated brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 143, 359-367.	2.9	35
76	Efficacy and safety of immune checkpoint blockade for brain metastases. <i>CNS Oncology</i> , 2019, 8, CNS33.	3.0	16
77	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. <i>Nature Neuroscience</i> , 2019, 22, 729-740.	14.8	327
78	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
79	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	27.8	956
80	The Misclassification of Diffuse Gliomas: Rates and Outcomes. <i>Clinical Cancer Research</i> , 2019, 25, 2656-2663.	7.0	42
81	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 290-299.	7.0	88
82	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2574-2584.	7.0	40
83	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	1.2	67
84	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	1.2	24
85	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
86	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1262-1271.	1.2	31
87	Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	4.1	38
88	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 349-356.	2.9	49
89	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	3.3	24
90	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	1.2	364

#	ARTICLE	IF	CITATIONS
91	Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncology, 2018, 14, 2507-2520.	2.4	32
92	Concepts for Immunotherapies in Gliomas. Seminars in Neurology, 2018, 38, 062-072.	1.4	26
93	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro-Oncology, 2018, 20, 225-235.	1.2	61
94	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology, 2018, 20, 259-267.	1.2	41
95	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology, 2018, 20, 249-258.	1.2	78
96	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology, 2018, 20, 838-847.	1.2	60
97	Neurological Complications of Immune-Based Therapies. , 2018, , 335-344.		0
98	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	35
99	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq1 1 0.784314 rgB Neuro-Oncology, 2018, 20, vi10-vi10.	1.2	6
100	Pseudoprogression: fact or wishful thinking in neuro-oncology?. Lancet Oncology, The, 2018, 19, 1561-1563.	10.7	16
101	PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology, 2018, 91, e1355-e1359.	1.1	64
102	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2018, 20, 897-906.	1.2	41
103	Immunotherapy for glioblastoma: going viral. Nature Medicine, 2018, 24, 1094-1096.	30.7	25
104	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	16.8	145
105	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research, 2018, 6, 1039-1045.	3.4	60
106	CRAN-11. MULTIPLEXED IMMUNOFLUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. Neuro-Oncology, 2018, 20, i39-i39.	1.2	2
107	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
108	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	1.2	80

#	ARTICLE	IF	CITATIONS
109	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
110	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	1.2	211
111	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	6.1	42
112	Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. <i>Neuroradiology</i> , 2017, 59, 135-145.	2.2	57
113	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	10.1	125
114	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	1.2	84
115	Angiogenesis inhibitors in tackling recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 507-515.	2.4	28
116	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	1.2	137
117	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017, 30, 361-369.	3.6	21
118	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	2.9	15
119	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 695-707.	27.6	90
120	ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS™ COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , 2017, 19, vi5-vi6.	1.2	0
121	High-grade Gliomas. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 1548-1563.	0.8	49
122	Immunotherapy for glioblastoma: on the sidelines or in the game?. <i>Discovery Medicine</i> , 2017, 24, 201-208.	0.5	31
123	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	1.8	100
124	Adult brainstem gliomas. <i>Cancer</i> , 2016, 122, 2799-2809.	4.1	35
125	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. <i>Cancer</i> , 2016, 122, 582-587.	4.1	33
126	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2016, 6, 217-225.	2.1	162

#	ARTICLE	IF	CITATIONS
127	Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. <i>Neuro-Oncology</i> , 2016, 18, 1680-1687.	1.2	94
128	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45
129	The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 864-871.	2.8	14
130	ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2016, 18, vi2-vi2.	1.2	1
131	Checkpoint inhibition in meningiomas. <i>Immunotherapy</i> , 2016, 8, 721-731.	2.0	22
132	Adult Atypical Teratoid/Rhabdoid Tumors. <i>World Neurosurgery</i> , 2016, 85, 197-204.	1.3	27
133	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86.	1.6	17
134	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	1.6	159
135	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655.	1.2	221
136	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	7.0	62
137	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016, 4, 124-135.	3.4	339
138	MAPK activation and <i>HRAS</i> mutation identified in pituitary spindle cell oncocytoma. <i>Oncotarget</i> , 2016, 7, 37054-37063.	1.8	27
139	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2015, 17, v6.2-v6.	1.2	2
140	Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 764-765.	1.2	0
141	Extent of resection and overall survival for patients with atypical and malignant meningioma. <i>Cancer</i> , 2015, 121, 4376-4381.	4.1	144
142	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	1.8	127
143	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	3.7	32
144	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. <i>Neuro-Oncology</i> , 2015, 17, 862-867.	1.2	111

#	ARTICLE	IF	CITATIONS
145	Unravelling tumour heterogeneityâ€™implications for therapy. Nature Reviews Clinical Oncology, 2015, 12, 69-70.	27.6	89
146	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology, 2015, 17, 854-861.	1.2	335
147	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 2015, 84, 280-286.	1.1	92
148	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	27.8	429
149	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 384-389.	0.8	46
150	Multicentric Low-Grade Gliomas. World Neurosurgery, 2015, 84, 1045-1050.	1.3	5
151	Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?. Immunotherapy, 2015, 7, 603-606.	2.0	13
152	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. Journal of Neuro-Oncology, 2015, 123, 339-346.	2.9	10
153	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	1.2	40
154	Brachytherapy in the treatment of recurrent aggressive falxine meningiomas. Journal of Neuro-Oncology, 2015, 124, 515-522.	2.9	10
155	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
156	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro-Oncology, 2015, 17, vii32-vii40.	1.2	21
157	Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 2015, 11, 504-514.	10.1	307
158	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Current Treatment Options in Oncology, 2015, 16, 54.	3.0	44
159	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	7.1	68
160	Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology, 2015, 17, 488-504.	1.2	114
161	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. Oncotarget, 2015, 6, 34030-34037.	1.8	17
162	One size should not fit all: advancing toward personalized glioblastoma therapy. Discovery Medicine, 2015, 19, 471-7.	0.5	13

#	ARTICLE	IF	CITATIONS
163	Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro-Oncology, 2014, 16, vii24-vii35.	1.2	32
164	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology, 2014, 16, vii36-vii47.	1.2	41
165	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology, 2014, 16, viii7-viii13.	1.2	85
166	Further delineating bevacizumab's response spectrum. Nature Reviews Clinical Oncology, 2014, 11, 243-244.	27.6	0
167	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. Clinical Cancer Research, 2014, 20, 5612-5619.	7.0	129
168	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro-Oncology, 2014, 16, 1523-1529.	1.2	22
169	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
170	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	1.2	164
171	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	1.2	80
172	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	1.2	0
173	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget, 2014, 5, 8083-8092.	1.8	55
174	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. Journal of Radiosurgery and SBRT, 2014, 3, 37-42.	0.2	3
175	Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opinion on Emerging Drugs, 2013, 18, 137-153.	2.4	29
176	Treatment Options in Newly Diagnosed Glioblastoma. Current Treatment Options in Neurology, 2013, 15, 281-288.	1.8	10
177	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Review of Vaccines, 2013, 12, 597-615.	4.4	60
178	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research, 2013, 19, 900-908.	7.0	112
179	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e71-e78.	3.8	5
180	Response to C. Massard et al. Journal of Clinical Oncology, 2012, 30, 563-564.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Treatment of elderly patients with glioblastoma. <i>Lancet Oncology</i> , The, 2012, 13, 656-657.	10.7	6
182	A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 245-250.	2.9	17
183	A Pilot Study of IL-2R α Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e31046.	2.5	98
184	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012, 118, 4759-4767.	4.1	26
185	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 499-506.	2.9	41
186	Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. <i>Journal of Neuro-Oncology</i> , 2012, 109, 63-70.	2.9	172
187	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 849-860.	2.3	18
188	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1507-1518.	2.3	59
189	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 281-287.	2.3	11
190	Phase II study of Gleevec [®] plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 409-415.	2.9	78
191	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 155-164.	2.9	123
192	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 107, 213-221.	2.9	24
193	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2027-2027.	1.6	1
194	Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2095-2095.	1.6	0
195	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2094-2094.	1.6	15
196	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2090-2090.	1.6	1
197	Cilengitide: an RGD pentapeptide α -D-Asp ¹ -D-Asp ² -D-Asp ³ -D-Asp ⁴ -D-Asp ⁵ integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011, 7, 339-354.	2.4	98
198	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011, 118, 3003-3012.	1.4	104

#	ARTICLE	IF	CITATIONS
199	A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 414-427.	4.9	113
200	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology, 2011, 101, 57-66.	2.9	118
201	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology, 2011, 103, 371-379.	2.9	83
202	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. Journal of Neuro-Oncology, 2011, 105, 621-627.	2.9	62
203	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer, 2011, 117, 5351-5358.	4.1	80
204	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRVIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011, 13, 324-333.	1.2	306
205	Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies. Genes and Cancer, 2011, 2, 1159-1165.	1.9	63
206	Advances in malignant glioma drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 739-753.	5.0	16
207	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	1.2	105
208	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology, 2010, 96, 219-230.	2.9	208
209	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 4722-4729.	1.6	702
210	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology, 2010, 12, 1300-1310.	1.2	207
211	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology, 2010, 12, 1061-1070.	1.2	112
212	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
213	Targeting multiple kinases in glioblastoma multiforme. Expert Opinion on Investigational Drugs, 2009, 18, 277-292.	4.1	39
214	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics, 2009, 8, 2773-2779.	4.1	262
215	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, 115, 2188-2198.	4.1	79
216	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of Neuro-Oncology, 2009, 95, 129-134.	2.9	47

#	ARTICLE	IF	CITATIONS
217	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	2.9	53
218	<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas. <i>New England Journal of Medicine</i> , 2009, 360, 765-773.	27.0	5,285
219	The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma. <i>Current Treatment Options in Oncology</i> , 2008, 9, 1-22.	3.0	32
220	Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 541-553.	3.1	73
221	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008, 10, 330-340.	1.2	41
222	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	7.0	166
223	Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2008, 26, 5610-5617.	1.6	448
224	A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. <i>Neuro-Oncology</i> , 2008, 10, 182-189.	1.2	95
225	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1225-1235.	4.1	174
226	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	1.6	1,285
227	Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 1253-1259.	7.0	1,005
228	Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 675-687.	2.4	68
229	Molecularly targeted therapy for malignant glioma. <i>Cancer</i> , 2007, 110, 13-24.	4.1	292
230	Recent Advances in the Treatment of Malignant Astrocytoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1253-1265.	1.6	285
231	Glioblastoma—more questions than answers?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 60-61.	4.3	2
232	Salvage Radioimmunotherapy With Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. <i>Journal of Clinical Oncology</i> , 2006, 24, 115-122.	1.6	186
233	Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. <i>Oncologist</i> , 2006, 11, 152-164.	3.7	206
234	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006, 47, 912-8.	5.0	32

#	ARTICLE	IF	CITATIONS
235	Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer, 2005, 103, 329-338.	4.1	116
236	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer, 2005, 104, 1478-1486.	4.1	76
237	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics, 2005, 4, 101-12.	4.1	176
238	Phase II Trial of Gefitinib in Recurrent Glioblastoma. Journal of Clinical Oncology, 2004, 22, 133-142.	1.6	677
239	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology, 2004, 6, 134-144.	1.2	42
240	Irinotecan: promising activity in the treatment of malignant glioma. Oncology, 2003, 17, 9-14.	0.5	8
241	Phase II Trial of Murine ¹³¹ I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas. Journal of Clinical Oncology, 2002, 20, 1389-1397.	1.6	227
242	The Current State of Glioma Data Registries. Neuro-Oncology Advances, 0, , .	0.7	1